[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![TacticzH Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1488239011378388997.png) TacticzHazel - Value Investing [@TacticzH](/creator/twitter/TacticzH) on x 12.6K followers
Created: 2025-07-09 20:29:31 UTC

2/ $NVO
Since Q1-2022
Revenue: + XXX%
EPS: +98.2%
Stock price: +25.86%

We all know what's happening here: $LLY came to join the party and execution has not been great. Therefore, they are losing market share.

Novo Nordisk is however taking matters into their own hands, and they started by firing their CEO. 

Their steady and fast growth, strong pipeline the tailwind from the growing obesity sector still provide significant upside potential. 

The two main questions are: can they keep up with $LLY and will the new CEO turn things around?

![](https://pbs.twimg.com/media/GvZoOzOW4AA2pKN.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1943044871041794202/c:line.svg)

**Related Topics**
[javascript](/topic/javascript)
[$novcde](/topic/$novcde)
[novo](/topic/novo)
[$lly](/topic/$lly)
[eps](/topic/eps)
[investment](/topic/investment)
[$nvo](/topic/$nvo)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/TacticzH/status/1943044871041794202)